According to the National Cancer Institute a biomarker is “a biological molecule found in blood, other body fluids or tissues that is a sign of a normal or abnormal process or of a condition or disease” (NCI) such as cancer.
Biomarkers typically differentiate an affected patient from a person without the disease. There is tremendous variety of biomarkers which can include:
A biomarker can also be a collection of alterations such as gene expression, proteomic, and metabolomic signatures.
Biomarkers can be detected in the circulation (whole blood, serum, or plasma) or excretions or secretions (stool, urine, sputum, or nipple discharge) and thus easily assessed non-invasively and serially. Biomarkers can also be tissue-derived and require either biopsy or special imaging for evaluation.
Sign up to learn about new research and developments from BioMark
Biomarkers have many potential applications in oncology including:
31
May, 2019
MAY 31, 2019 — Glioblastoma multiforme (GBM) is the most common primary brain tumour in adults and is characterized by its infiltrative and often fatal progression. The strikingly poor survival for patients with GBM of 14-16 months following diagnosis is…
READ MORE
30
May, 2019
Follow-up evaluation of outliers with elevated spermine-spermidine acetyltransferase-1 activity. Sub-category: Circulating Biomarkers Category: Developmental Therapeutics and Tumor Biology (Nonimmuno) Meeting: 2019 ASCO Annual Meeting Abstract No: e14536 Citation: J Clin Oncol 37, 2019 (suppl; abstr e14536) Author(s): Andrew W. Maksymiuk, Paramjit S. Tappia, Bram Ramjiawan, Nazrina Khatun, Rahnuma Parveen, Rashiduzzaman Ahmed, Gina Huang, Rashid Bux Ahmed, Parveen S. Akhtar, Horacio Bach, Daniel Sitar; CancerCare Manitoba, Winnipeg, MB, Canada; Asper Clinical Research…
READ MOREMay 30, 2019
Vancouver, British Columbia – (May 30th, 2019) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX); (FSE: 20B); (OTCMKTS: BMKDF) is pleased to announce that its patent titled “DETECTION AND QUANTIFICATION OF ACETYLAMANTADINE IN URINE SAMPLES” has been recently granted in United States. Rashid Ahmed, President and CEO, says, “Granting of this patent expands and strengthens our metabolite measurement capabilities by offering options to cost effectively and reliably quantify the substrate of interest (acetylamantadine) in a biological sample for our SSAT1 urine-based assay using Raman spectroscopy. This technology can be used […]
BioMark has been over the years, funded by various government agencies and Foundation including NRC IRAP, NRC Engage, Genome BC, Government of Manitoba and DFAIT Canada for various projects with active collaboration at University of British Columbia, University of Manitoba, University of Victoria, University of Waterloo, and University of Alberta. Now BioMark is collaborating with Bio banks across Canada and United States to expand our metabolomics study.